New anticoagulant drugs

Journal of Thrombosis and Thrombolysis

Volumn 12, Issue 1, 2001, Pages 7-17

  Weitz, J I ^a  

^a NONE   (Canada)

Author keywords

Anticoagulant; Therapy; Thrombosis

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 3 [3 (AMINOIMINOMETHYL)PHENYL] 5 [(2' AMINOSULFONYL 1,1' BIPHENYL 4 YL)CARBAMOYL] 4,5 DIHYDRO 5 ISOXAZOLEACETIC ACID METHYL ESTER; 3 [3 (AMINOIMINOMETHYL)PHENYL] N (2' AMINOSULFONYL 1,1' BIPHENYL 4 YL) 4,5 DIHYDRO 5 (1H TETRAZOL 1 YLMETHYL) 5 ISOXAZOLECARBOXAMIDE; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING INHIBITOR; DERMATAN SULFATE; FIBRIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HEPARIN COFACTOR II; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NEMATODE ANTICOAGULANT PEPTIDE C2; PENTASACCHARIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SODIUM N [8 (2 HYDROXYBENZOYL)AMINO]OCTANOIC ACID; THROMBIN INHIBITOR; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TRIDEGIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLEEDING DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG COST; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ERYTHROCYTE; FATALITY; FIBRIN CLOT; FIBRIN DEPOSITION; GANGRENE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LUNG EMBOLISM; MORBIDITY; MORTALITY; NONHUMAN; PHLEBITIS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOGENESIS; TREATMENT PLANNING; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; HUMANS; THROMBOSIS; VENOUS THROMBOSIS;

EID: 0035184966     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013089924994     Document Type: Conference Paper

References (96)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Molecular and cellular biology of blood coagulation
3. Tissue factor expression during monocyte-macrophage differentiation
4. Tissue factor-dependent autoactivation of human blood coagulation factor
5. Factor XI activation by thrombin and factor XIa
6. Heparin
7. Low molecular weight heparins
8. Insight into the mechanism of action of heparin cofactor II
9. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino] caprylate: Pharmacological considerations
10. Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group
11. Bioavailability of Desmin, a low molecular weight dermatan sulphate, after subcutaneous administration to healthy volunteers
12. Structural features of dermatan sulfates and their relationship to anticoagulant antithrombotic activities
13. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy
14. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-dependent inhibitors
15. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors
16. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4
17. Cloning and expression of cDNA coding for the anticoagulant hirudin from blood sucking leech, Hirudo medicinalis
18. Kinetics of inhibition of thrombin by hirudin
19. The structure of a complex of recombinant hirudin and human-thrombin
20. Hirudins: Antithrombin anticoagulants
21. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia
22. Hirudin therapy for heparin-associated thrombocytopenia and deep venous thrombosis
23. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man
24. Recombinant hirudin as an anticoagulant in open-heart surgery; a case report
25. New treatment options for heparin-induced thrombocytopenia
26. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393
27. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement
28. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study
29. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation: A randomized trial
30. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors or thrombin
31. Thrombin-specific inhibition by and slow cleavage of hirulog-1
32. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators
33. A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators
34. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans
35. Argatroban: A synthetic thrombin inhibitor of low relative molecular mass
36. Single and repeated oral dosing of H376/95, a prodrug of the direct thrombin inhibitor melagatran, to young healthy male subjects
37. Pharmacodynamic properties of H376/95, a prodrug of the direct thrombin inhibitor melagatran, intended for oral use
38. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model
39. A monoclonal antibody to factor IX that inhibits the factor VIII: Ca potentiation of factor X activation
40. An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis
41. Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats
42. Biochemical and pharmacological properties of SANORG 340006, a potent and long-acting synthetic pentasaccharide
43. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
44. The Ephesus Study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery
45. The Penthifra Study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) after hip fracture surgery
46. The Pentamaks Study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective major knee surgery
47. Structural and functional characterization of tick anticoagulant peptide (TAP): A potent and selective inhibitor of blood coagulation factor Xa
48. Isolation and characterization of antistasin
49. Antistasin: A leech-derived inhibitor of factor Xa: Kinetic analysis of enzyme inhibition and identification of the reactive site
50. A new factor Xa inhibitor (lefaxin) from the Haementeria depressa leech
51. DX-9065a, a novel, synthetic, selective and orally active inhibitor of factor Xa: In vitro and in vivo studies
52. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa
53. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new antithrombotic
54. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors
55. Tissue factor pathway inhibitor
56. Anticoagulant repertoire of the hookworm Ancylostoma caninum
57. Ancylostoma caninum anticoagulant peptide: A hookworm-derived inhibitor of human coagulation factor Xa
58. A dose-response study of the factor VIIa/tissue factor inhibitor rNAPc2 in the prevention of postoperative venous thrombosis in patients undergoing total knee arthroplasty
59. The protein C pathway: New insights
60. Efficacy and safety of recombinant human activated protein C for severe sepsis
61. Thrombomodulin structure and function
62. Stable expression of a secretable deletion mutation of recombinant human thrombomodulin in mammalian cells
63. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice
64. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III
65. Conversion of thrombin into an anticoagulant by protein engineering
66. Modulation of thrombin's procoagulant and anticoagulant properties
67. Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator
68. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil
69. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin: A potential link between lipid lowering and fibrinolysis
70. The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into sheet A
71. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro
72. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces post-thrombolysis thrombus growth in rabbits
73. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
74. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B
75. Inducible carboxypeptidase activity: A role in clot lysis in vivo
76. A novel approach to arterial thrombolysis
77. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains
78. The roles of fibrinogen and fibrin in hemostasis and thrombosis
79. Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function
80. Tridegin, a novel peptidic inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro
81. Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii
82. Destabilase, the novel epsilon-(gamma-Glu)-Lys isopeptidase with thrombolytic activity
83. Genes from the medicinal leech (Hirudo medicinalis) coding for unusual enzymes that specifically cleave endo-epsilon (gamma-Glu)-Lys isopeptide bonds and help to dissolve blood clots
84. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomized comparison of enoxaparin and placebo
85. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
86. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin (Fragmin)
87. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind controlled study in humans
88. Orally administered heparin for preventing deep venous thrombosis
89. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis
90. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
91. The long-term clinical course of acute deep venous thrombosis
92. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
93. Hirudin in acute myocardial infarction: Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial
94. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
95. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO IIb trial
96. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)